FDA approves first Lucentis injection biosimilar for treating eye diseases

The FDA announced today that it approved Samsung Bioepis’ Byooviz injection, making it the first approved biosimilar to Lucentis for treating eye diseases.

Byooviz (ranibizumab-nuna), the first biosimilar to Lucentis (ranibizumab injection), treats several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD). The treatment is administered by intravitreal injection (delivered into the vitreous humor of the eye) once a month.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0